Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 64.2 GBX -1.53% Market Closed
Market Cap: 255.5m GBX
Have any thoughts about
Niox Group PLC?
Write Note

Niox Group PLC
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Niox Group PLC
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
Operating Expenses
-ÂŁ22.2m
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Expenses
-$178.1m
CAGR 3-Years
-157%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Expenses
-$177.2m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Expenses
-$233.4m
CAGR 3-Years
-45%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Expenses
-ÂŁ308m
CAGR 3-Years
-37%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Expenses
-ÂŁ614.6m
CAGR 3-Years
-6%
CAGR 5-Years
-36%
CAGR 10-Years
-6%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
272.2m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
48.29 GBX
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Niox Group PLC's Operating Expenses?
Operating Expenses
-22.2m GBP

Based on the financial report for Jun 30, 2024, Niox Group PLC's Operating Expenses amounts to -22.2m GBP.

What is Niox Group PLC's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
19%

Over the last year, the Operating Expenses growth was -7%. The average annual Operating Expenses growth rates for Niox Group PLC have been 9% over the past three years , 19% over the past five years .

Back to Top